2017 Universal Access & Affordable Medicines Forum of the European Public Health Alliance (EPHA)
GAME CHANGERS
FOR BETTER AND AFFORDABLE MEDICINES FOR EUROPE
Under the auspices of the Bulgarian Ministry of Health
November 21, 2017 • 9AM – 6PM
Martin’s Brussels EU Hotel
Boulevard Charlemagne 80, 1000 Brussels
#GameChangers was a day full of stimulating and lively discussions on the hottest topics in the access to medicines debate:
– Incentives in drug development: Towards profiteering or genuine innovation?
– The push for accelerated approvals: Speed and deregulation over patient safety and robust evidence?
– Transparency in pharmaceuticals: Desirable &/or feasible?
– Business strategies, anti-competitive practices & medicines’ shortages: What is the way out?
About the event
Programme
08.45 – 09.15
REGISTRATION AND COFFEE
09.15 – 09.45
WELCOMING REMARKS
09.45 – 11.15
PANEL 1: Transparency in pharmaceuticals: desirable and/or feasible?
11.30 – 13.00
PANEL 2: Drug development: do the incentives work?
13.45 – 15.15
PANEL 3: The push for accelerated drug approvals: speed and deregulation over patient safety and robust evidence?
15.30 – 17.00
PANEL 4: Business strategies, anti-competitive practices & medicines’ shortages: what is the way out?
17.00-18.00
NETWORKING RECEPTION
Speakers
Zlatimira Dobreva,
Representative of the Ministry of Health, Bulgaria
Andrzej Rys,
Director Responsible for Health Systems, Medical Products and Innovation, Directorate-General for Health and Food Safety (DG SANTE), European
Commission
Yannis Natsis,
Policy Manager, Universal Access and Affordable Medicines, European Public Health Alliance (EPHA)
Dr Andrew Hill,
Senior Visiting Research Fellow, Department of Pharmacology and Therapeutics, Liverpool University
Dr Síle Lane,
Head, International Campaigns and Policy, Sense about Science, UK
Francis Arickx,
Head, Pharmaceutical Department, National Institute for Health and Disability Insurance (RIZIV INAMI)
Aldo Golja,
Senior Policy Advisor, Pricing and Reimbursement-Coordinator of the BeNeLuxA Initiative on Pharmaceutical Policy, Ministry of Health, Welfare and Sport,
The Netherlands
Boris Azais,
Director, Public Policy for Europe and Canada, MSD
Dyfrig Hughes,
Professor of Pharmacoeconomics, School of Healthcare Sciences, Bangor University, Co-Director, Centre for Health Economics & Medicines Evaluation
Els Torreele,
Executive Director, Access Campaign, Médecins Sans Frontières (MSF)
Elizabeth Kuiper,
Executive Director Public Affairs European Federation of Pharmaceutical Industries and Associations, EFPIA
Marcel Canoy,
Advisor, Netherlands Authority for Consumers and Markets (ACM)
Claudia Wild,
Director, Ludwig Boltzmann Institute for Health Technology Assessment
Antonio Addis,
Researcher, Department of Epidemiology, Regional Health Service,
Rome
Simon Collins,
Patient Advocate, HIV i-Base
Beate Wieseler,
Head, Department of Drug Assessment, Institute for Quality and Efficiency in Health Care
Helen Lee,
Unit B5 – Medicines: policy, authorisation and monitoring DG Santé,
European Commission
Marc-Alexander Mahl,
President, Medicines for Europe
Aida Batista,
Vice-President, European Association of Hospital Pharmacists (EAHP)
Fernando Lamata,
Senior Expert on Health Care Policies, Impeller of the Association for a Fair Access to Medicines, Spain
Vlad Voiculescu,
Member, Romanian Health Observatory
Rainer Becker,
Head of Unit for Antitrust Pharma and Health services, Directorate General for Competition (DG COMP), European Commission
Re-live the event
Event Gallery
In the Press
Re-live the online discussion
"#Beneluxa is countries coming together to see if voluntary collaboration can work. We were able to go throught the whole process together, collaboration so far was succesful. We'll be able to expand and move forward." Aldo Golja @MinVWS #GameChangers
— EPHA (@EPHA_EU) November 21, 2017
Important to look the links between incentives with pricing/business strategies of #pharma companies #GameChangers
— Yannis Natsis (@YNatsis) November 21, 2017
I can’t believe we are still arguing with #Pharma about whether we have a problem with too expensive medicines while the house is on fire #GameChangers
— Els Torreele (@ElsTorreele) November 21, 2017
Main message of 1st panel of #GAMECHANGERS on transparency in pharma: both payers and industry need to be more transparent about what they want.
— Charlotte Roffiaen (@EU4Ublog) November 21, 2017
Without incentives and rewards for private research there is no innovation, says @borisazais #gamechangers @EFPIA
— Elizabeth Kuiper (@kuiper_em) November 21, 2017
.@BGPermRepEU asks why we can't have a frank discussion on the definition of "Unmet medical need". #GameChangers @EMA_News @EU_Health
— Catta (@CattaFra) November 21, 2017
We've been following a fascinating and topical discussion about #access2meds, #incentives and #rarediseases at @EPHA_EU's #GameChangers event today pic.twitter.com/nY96aiybJe
— acumen public affairs (@AcumenPA) November 21, 2017
